Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VYTORIN

« Back to Dashboard
Vytorin is a drug marketed by Msd Intl and is included in one NDA. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VYTORIN is ezetimibe; simvastatin. There are eighteen drug master file entries for this compound. Five suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the ezetimibe; simvastatin profile page.

Summary for Tradename: VYTORIN

Suppliers / Packagers: see list36
2013 Sales:$858,576,000

Clinical Trials for: VYTORIN

Vytorin in the Treatment of Alopecia Areata
Status: Completed Condition: Alopecia Areata

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
Status: Completed Condition: Hypercholesterolemia; Hyperlipidemia

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
Status: Not yet recruiting Condition: Metabolic Syndrome

Vytorin Reexamination Study (0653A-174)
Status: Completed Condition: Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
Status: Completed Condition: Hypercholesterolemia

Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)(COMPLETED)
Status: Completed Condition: Hyperlipidemia

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
Status: Active, not recruiting Condition: Inflammation

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Dyslipidemia

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)
Status: Completed Condition: Hypercholesterolemia

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
Status: Completed Condition: Hypercholesterolemia; Myocardial Infarction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687-001Jul 23, 2004RXNoRE42461*PED<disabled> <disabled>
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687-003Jul 23, 2004RXNoRE42461*PED<disabled> <disabled>
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687-002Jul 23, 2004RXNoRE42461*PED<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VYTORIN

Drugname Dosage Strength RLD Submissiondate
ezetimibe and simvastatinTablets10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mgVytorin7/27/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn